HER2-negative Breast Cancer trials recruiting in Massachusetts

All HER2-negative Breast Cancer trials nationally

Cities in Massachusetts

Recruiting trials in Massachusetts

• DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
  NCT06176261 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
  NCT07198724 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
  NCT05216432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
  NCT05508906 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
  NCT06982521 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
  NCT06488378 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
  NCT05467891 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
  NCT04150042 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Sacituzumab Govitecan In TNBC
  NCT04230109 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston, Danvers, Newton
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · Massachusetts: Boston